Reposted from HDBuzz.net
UniQure has announced positive top-line results from its Phase I/II trial of AMT-130, a one-time gene therapy being tested in people with Huntington’s disease (HD). Topline data is a summary of the key results from a study that is released quickly after data becomes available to the company at a specified timepoint. In this update, uniQure reports that symptom progression is being significantly slowed by the drug, and the primary endpoint of the trial was met. This is the first time any drug has been shown to alter the course of HD in people in a clinical trial. HDBuzz caught up with uniQure’s Chief Medical Officer Walid Abi-Saab and CEO Matt Kapusta to get clarity for the HD community around this update. Let’s get into the details of this drug and the update uniQure have shared.
More News
Image
2T6 valedictorian Julia Ioannou reflects on personal and professional growth during PharmD program
From athletics to student government, Julia Ioannou took on leadership roles and helped enhance student life at the Leslie Dan Faculty of Pharmacy.
Read More
Image
Discovery Pharmacy helps students see full potential of pharmacy practice
Sydney Schroeder and Preston Chan reflect on their experiences at Discovery Pharmacy throughout their PharmD degree.
Read More
Image
New research explores the biology of forgetting
PhD graduate Quinn Pauli examines how connections between neurons change during learning and forgetting.
Read More